2024 Q3 Form 10-Q Financial Statement

#000121390024069173 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q4
Revenue $2.541M $3.431M $1.017M
YoY Change 200.71% 80.96% -59.87%
Cost Of Revenue $798.0K $1.488M $663.0K
YoY Change 28.92% 17.72% -54.68%
Gross Profit $1.743M $1.943M $354.0K
YoY Change 671.24% 207.44% -66.95%
Gross Profit Margin 68.6% 56.63% 34.81%
Selling, General & Admin $1.517M $1.437M $1.424M
YoY Change -8.72% -14.52% -39.61%
% of Gross Profit 87.03% 73.96% 402.26%
Research & Development $543.0K $603.0K $585.0K
YoY Change -21.42% -9.87% -18.41%
% of Gross Profit 31.15% 31.03% 165.25%
Depreciation & Amortization $3.000K $4.000K $7.000K
YoY Change -70.0% -33.33% -216.67%
% of Gross Profit 0.17% 0.21% 1.98%
Operating Expenses $2.060M $1.877M $2.009M
YoY Change -12.45% -20.13% -34.67%
Operating Profit -$317.0K $66.00K -$1.655M
YoY Change -85.1% -103.84% -17.42%
Interest Expense -$194.0K -$144.0K -$276.0K
YoY Change -220.5% -184.21% -42.26%
% of Operating Profit -218.18%
Other Income/Expense, Net
YoY Change
Pretax Income -$511.0K -$78.00K -$1.931M
YoY Change -41.26% -95.1% -22.2%
Income Tax
% Of Pretax Income
Net Earnings -$511.0K -$78.00K -$1.931M
YoY Change -41.06% -95.1% -22.2%
Net Earnings / Revenue -20.11% -2.27% -189.87%
Basic Earnings Per Share -$0.09 -$0.01
Diluted Earnings Per Share -$0.09 -$0.01 -$0.67
COMMON SHARES
Basic Shares Outstanding 6.016M shares 3.354M shares 2.716M shares
Diluted Shares Outstanding 6.015M shares 4.258M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.241M $2.412M $817.0K
YoY Change 138.4% -28.68% -85.32%
Cash & Equivalents $2.241M $2.412M $620.0K
Short-Term Investments $0.00 $0.00 $197.0K
Other Short-Term Assets $781.0K $1.281M $1.905M
YoY Change -27.01% 38.64% 68.73%
Inventory $2.372M $2.158M $2.526M
Prepaid Expenses $198.0K
Receivables $1.828M $690.0K $664.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.222M $6.541M $5.912M
YoY Change 33.37% -16.92% -45.8%
LONG-TERM ASSETS
Property, Plant & Equipment $52.00K $55.00K $61.00K
YoY Change -21.21% -21.43% -23.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.476M $1.761M $5.250M
YoY Change -74.01% -68.73% 37.0%
Total Long-Term Assets $1.528M $1.816M $5.311M
YoY Change -73.39% -68.15% 35.76%
TOTAL ASSETS
Total Short-Term Assets $7.222M $6.541M $5.912M
Total Long-Term Assets $1.528M $1.816M $5.311M
Total Assets $8.750M $8.357M $11.22M
YoY Change -21.58% -38.43% -24.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $893.0K $1.421M $1.769M
YoY Change -59.22% -25.91% -0.67%
Accrued Expenses $2.218M $2.557M $2.682M
YoY Change 6.63% 11.08% 125.38%
Deferred Revenue $277.0K $206.0K $389.0K
YoY Change
Short-Term Debt $927.0K $1.045M $0.00
YoY Change
Long-Term Debt Due $460.0K $1.335M
YoY Change -62.39% 141.41%
Total Short-Term Liabilities $5.075M $6.471M $6.912M
YoY Change -23.47% -3.65% 11.45%
LONG-TERM LIABILITIES
Long-Term Debt $150.0K $263.0K $3.154M
YoY Change -95.28% -92.39% -31.81%
Other Long-Term Liabilities $16.00K $27.00K $769.0K
YoY Change -36.0% -15.63% 5.78%
Total Long-Term Liabilities $614.0K $749.0K $3.923M
YoY Change -82.87% -86.3% -26.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.075M $6.471M $6.912M
Total Long-Term Liabilities $614.0K $749.0K $3.923M
Total Liabilities $5.689M $7.220M $10.84M
YoY Change -44.31% -40.75% -6.22%
SHAREHOLDERS EQUITY
Retained Earnings -$42.26M -$41.75M -$39.69M
YoY Change 11.93% 13.18% 18.82%
Common Stock $1.000K $1.000K $39.92M
YoY Change -100.0% 0.0% 3991600.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.833M $936.0K $388.0K
YoY Change
Total Liabilities & Shareholders Equity $8.750M $8.357M $11.22M
YoY Change -21.58% -38.43% -24.27%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q4
OPERATING ACTIVITIES
Net Income -$511.0K -$78.00K -$1.931M
YoY Change -41.06% -95.1% -22.2%
Depreciation, Depletion And Amortization $3.000K $4.000K $7.000K
YoY Change -70.0% -33.33% -216.67%
Cash From Operating Activities -$2.438M -$2.140M -$1.387M
YoY Change 8.36% 73.42% -30.37%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$1.000K
YoY Change -100.0% -97.06%
Acquisitions
YoY Change
Other Investing Activities $0.00 $198.0K $2.390M
YoY Change -100.0% -80.42% -160.26%
Cash From Investing Activities $0.00 $198.0K $2.391M
YoY Change -100.0% -80.42% -160.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.621M 167.0K 1.171M
YoY Change -953.16% -94.47% -257.82%
NET CHANGE
Cash From Operating Activities -2.438M -2.140M -1.387M
Cash From Investing Activities 0.000 198.0K 2.391M
Cash From Financing Activities 1.621M 167.0K 1.171M
Net Change In Cash -817.0K -1.775M 2.175M
YoY Change -51.66% -163.42% -132.63%
FREE CASH FLOW
Cash From Operating Activities -$2.438M -$2.140M -$1.387M
Capital Expenditures $0.00 $0.00 -$1.000K
Free Cash Flow -$2.438M -$2.140M -$1.386M
YoY Change 7.88% 73.42% -29.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2033747 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.72
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2333381 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4000994 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41375
dei Entity Registrant Name
EntityRegistrantName
ACTELIS NETWORKS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2160309
dei Entity Address Address Line1
EntityAddressAddressLine1
4039 Clipper Court
dei Entity Address City Or Town
EntityAddressCityOrTown
Fremont
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94538
dei City Area Code
CityAreaCode
(510)
dei Local Phone Number
LocalPhoneNumber
545-1045
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
ASNS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6016326 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2412000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
620000 usd
CY2024Q2 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
790000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
6541000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5912000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61000 usd
CY2024Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
592000 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
592000 usd
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
160000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3330000 usd
CY2024Q2 asns Restricted Bank Deposits Noncurrent
RestrictedBankDepositsNoncurrent
89000 usd
CY2023Q4 asns Restricted Bank Deposits Noncurrent
RestrictedBankDepositsNoncurrent
94000 usd
CY2024Q2 asns Severance Pay Fund Noncurrent
SeverancePayFundNoncurrent
235000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
608000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
918000 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
78000 usd
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
1816000 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
5311000 usd
CY2024Q2 us-gaap Assets
Assets
8357000 usd
CY2023Q4 us-gaap Assets
Assets
11223000 usd
CY2024Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1045000 usd
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
460000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1335000 usd
CY2024Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1421000 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1769000 usd
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
206000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
389000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
782000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
737000 usd
CY2024Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1119000 usd
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1062000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
443000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
498000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
995000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1122000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6912000 usd
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
263000 usd
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
45000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
151000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
405000 usd
CY2024Q2 asns Accrued Severance Noncurrent
AccruedSeveranceNoncurrent
263000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
27000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23000 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
749000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3923000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
7220000 usd
CY2023Q4 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
1565000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
197000 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
168000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
168000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
690000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
664000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
2158000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
2526000 usd
CY2024Q2 asns Allowance For Doubtful Debts Prepaid Expenses
AllowanceForDoubtfulDebtsPrepaidExpenses
181000 usd
CY2023Q4 asns Allowance For Doubtful Debts Prepaid Expenses
AllowanceForDoubtfulDebtsPrepaidExpenses
144000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
491000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
340000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
6541000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5912000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55000 usd
CY2024Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
592000 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
592000 usd
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
160000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3330000 usd
CY2024Q2 asns Restricted Bank Deposits Noncurrent
RestrictedBankDepositsNoncurrent
89000 usd
CY2023Q4 asns Restricted Bank Deposits Noncurrent
RestrictedBankDepositsNoncurrent
94000 usd
CY2024Q2 asns Severance Pay Fund Noncurrent
SeverancePayFundNoncurrent
235000 usd
CY2023Q4 asns Severance Pay Fund Noncurrent
SeverancePayFundNoncurrent
238000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
608000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
918000 usd
CY2024Q2 us-gaap Long Term Investments
LongTermInvestments
77000 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
78000 usd
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
1816000 usd
CY2024Q2 us-gaap Assets
Assets
8357000 usd
CY2024Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1045000 usd
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
460000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1335000 usd
CY2024Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1421000 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1769000 usd
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
206000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
782000 usd
CY2024Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1119000 usd
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1062000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
443000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
498000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
995000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1122000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6471000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6912000 usd
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
263000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3154000 usd
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
45000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
71000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
151000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
405000 usd
CY2024Q2 asns Accrued Severance Noncurrent
AccruedSeveranceNoncurrent
263000 usd
CY2023Q4 asns Accrued Severance Noncurrent
AccruedSeveranceNoncurrent
270000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
27000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23000 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
749000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3923000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
7220000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
10835000 usd
CY2024Q2 asns Warrants To Placement Agent
WarrantsToPlacementAgent
201000 usd
CY2023Q4 asns Warrants To Placement Agent
WarrantsToPlacementAgent
159000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5017322 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5017322 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3007745 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3007745 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
42687000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
39916000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41752000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39688000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
936000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8357000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11223000 usd
us-gaap Revenues
Revenues
4157000 usd
us-gaap Revenues
Revenues
3744000 usd
CY2024Q2 us-gaap Revenues
Revenues
3431000 usd
CY2023Q2 us-gaap Revenues
Revenues
1896000 usd
us-gaap Cost Of Revenue
CostOfRevenue
2424000 usd
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
1488000 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
1264000 usd
us-gaap Gross Profit
GrossProfit
1320000 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
1943000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
632000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1250000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1426000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
603000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
669000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1274000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1641000 usd
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
647000 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
712000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1607000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1834000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
790000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
969000 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
163000 usd
CY2024Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
163000 usd
us-gaap Operating Expenses
OperatingExpenses
3968000 usd
us-gaap Operating Expenses
OperatingExpenses
4901000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1877000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
2350000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1805000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3581000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
66000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1718000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
344000 usd
CY2024Q2 asns Warrants To Placement Agent
WarrantsToPlacementAgent
201000 usd
CY2023Q4 asns Warrants To Placement Agent
WarrantsToPlacementAgent
159000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5017322 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5017322 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
42687000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
39916000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41752000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39688000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
936000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
229000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8357000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11223000 usd
us-gaap Revenues
Revenues
4157000 usd
us-gaap Revenues
Revenues
3744000 usd
CY2024Q2 us-gaap Revenues
Revenues
3431000 usd
CY2023Q2 us-gaap Revenues
Revenues
1896000 usd
us-gaap Cost Of Revenue
CostOfRevenue
1994000 usd
us-gaap Cost Of Revenue
CostOfRevenue
2424000 usd
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
1488000 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
1264000 usd
us-gaap Gross Profit
GrossProfit
2163000 usd
us-gaap Gross Profit
GrossProfit
1320000 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
1943000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
632000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1250000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1426000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
603000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1274000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1641000 usd
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
647000 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
712000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1607000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1834000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
790000 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
163000 usd
CY2024Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
163000 usd
us-gaap Operating Expenses
OperatingExpenses
3968000 usd
us-gaap Operating Expenses
OperatingExpenses
4901000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1877000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
2350000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1805000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3581000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
66000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1718000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
351000 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
137000 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
171000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
85000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
444000 usd
CY2024Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
7000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
351000 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
137000 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
171000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
85000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
444000 usd
CY2024Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
7000 usd
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
296000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2064000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3488000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1593000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4000994 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2033747 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4257674 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2333381 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3265000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
192000 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
50000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1356000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3488000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
229000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
179000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2560000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
936000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1415000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
97000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1593000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1285000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1668000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
90000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2560000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-78000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
936000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2064000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3488000 usd
us-gaap Depreciation
Depreciation
8000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-396000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
223000 usd
us-gaap Inventory Write Down
InventoryWriteDown
25000 usd
us-gaap Inventory Write Down
InventoryWriteDown
97000 usd
asns Exchange Rate Difference
ExchangeRateDifference
79000 usd
asns Exchange Rate Difference
ExchangeRateDifference
226000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
179000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
192000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
64000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1275000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-24000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-342000 usd
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
296000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2064000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3488000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1593000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2033747 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4257674 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2333381 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3265000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
192000 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
50000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1356000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3488000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1285000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
229000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
179000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2560000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2064000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
936000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1415000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
97000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1356000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1593000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1285000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1668000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
90000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2560000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-78000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
936000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3488000 usd
us-gaap Depreciation
Depreciation
8000 usd
us-gaap Depreciation
Depreciation
13000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-396000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
223000 usd
us-gaap Inventory Write Down
InventoryWriteDown
25000 usd
us-gaap Inventory Write Down
InventoryWriteDown
97000 usd
asns Exchange Rate Difference
ExchangeRateDifference
79000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
192000 usd
us-gaap Interest Expense
InterestExpense
-41000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
64000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
26000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1275000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
726000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
150000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-208000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-347000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
137000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-209000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
726000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
150000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-208000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-347000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
137000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-209000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-155000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
14000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-36000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-17000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2343000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2939000 usd
asns Proceedsfrom Short Term Deposits
ProceedsfromShortTermDeposits
198000 usd
asns Proceedsfrom Short Term Deposits
ProceedsfromShortTermDeposits
810000 usd
asns Paymentto Short Term Restricted Bank Deposits
PaymenttoShortTermRestrictedBankDeposits
125000 usd
asns Payments For Proceeds From Long Term Deposit
PaymentsForProceedsFromLongTermDeposit
5000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
197000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
677000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
50000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3500000 usd
asns Proceeds From Warrant Inducement Agreement
ProceedsFromWarrantInducementAgreement
2999000 usd
asns Underwriting Discounts And Commissions And Other Offering Costs
UnderwritingDiscountsAndCommissionsAndOtherOfferingCosts
397000 usd
asns Underwriting Discounts And Commissions And Other Offering Costs
UnderwritingDiscountsAndCommissionsAndOtherOfferingCosts
291000 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1045000 usd
us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
-3483000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
193000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
389000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2780000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-10000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-10000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2153000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
508000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5515000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4279000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3362000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4787000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2412000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2573000 usd
CY2024Q2 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
160000 usd
CY2023Q2 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
2214000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3362000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4787000 usd
us-gaap Interest Paid Net
InterestPaidNet
326000 usd
us-gaap Interest Paid Net
InterestPaidNet
351000 usd
asns Issuance Costs Of Common Stock Prefunded Warrants And Warrants
IssuanceCostsOfCommonStockPrefundedWarrantsAndWarrants
104000 usd
asns Issuance Costs Of The Warrant Inducement Agreement
IssuanceCostsOfTheWarrantInducementAgreement
1493000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2064000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2343000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2939000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41752000 usd
CY2024Q2 us-gaap Cash
Cash
3202000 usd
CY2024Q2 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
249000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-155000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
14000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-36000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-17000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2343000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2939000 usd
asns Proceedsfrom Short Term Deposits
ProceedsfromShortTermDeposits
198000 usd
asns Proceedsfrom Short Term Deposits
ProceedsfromShortTermDeposits
810000 usd
asns Paymentto Short Term Restricted Bank Deposits
PaymenttoShortTermRestrictedBankDeposits
125000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
197000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
677000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
50000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3500000 usd
asns Proceeds From Warrant Inducement Agreement
ProceedsFromWarrantInducementAgreement
2999000 usd
asns Underwriting Discounts And Commissions And Other Offering Costs
UnderwritingDiscountsAndCommissionsAndOtherOfferingCosts
397000 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1045000 usd
us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
-3483000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
193000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
389000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2780000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-10000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-10000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2153000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
508000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5515000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4279000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4787000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2412000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2573000 usd
CY2024Q2 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
790000 usd
CY2024Q2 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
160000 usd
CY2023Q2 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
2214000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3362000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4787000 usd
us-gaap Interest Paid Net
InterestPaidNet
326000 usd
us-gaap Interest Paid Net
InterestPaidNet
351000 usd
asns Issuance Costs Of Common Stock Prefunded Warrants And Warrants
IssuanceCostsOfCommonStockPrefundedWarrantsAndWarrants
104000 usd
asns Issuance Costs Of The Warrant Inducement Agreement
IssuanceCostsOfTheWarrantInducementAgreement
1493000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2064000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2939000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41752000 usd
CY2024Q2 us-gaap Cash
Cash
3202000 usd
CY2024Q2 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
249000 usd
us-gaap Other Income
OtherIncome
163 usd
us-gaap Other Income
OtherIncome
163 usd
us-gaap Use Of Estimates
UseOfEstimates
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>b.</b></td><td style="text-align: justify"><b>Use of estimates in preparation of financial statements</b></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, fair values of financial instruments, inventory write-offs, as well as in estimates used in applying the revenue recognition policy. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>d.</b></td><td style="text-align: justify"><b>Concentration of risk</b></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash and cash equivalents, trade receivables and other current assets. Cash and cash equivalents and restricted cash and cash equivalents are placed with banks and financial institutions in the United States and Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, present minimal credit risk with respect to those investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company’s trade receivables are derived primarily from telecommunication operators, the Company’s reseller customers and enterprises located mainly in the United States, Europe, and Asia.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Credit risk with respect to trade receivables exists to the full extent of the amounts presented in the consolidated financial statements. Management makes judgments as to its ability to collect outstanding accounts receivable and provides allowances for the applicable portion of accounts receivable when collection becomes doubtful.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Management provides allowances based upon a specific review of all significant outstanding invoices, analysis of its historical collection experience, and current economic trends. If the historical data used to calculate the allowance for credit losses does not reflect the Company’s future ability to collect outstanding accounts receivable, additional provisions for credit losses may be needed, and the future results of operations could be materially affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company has customers balances representing 10% or more of Trade receivables as follows:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer A represented </span><span style="font-size: 10pt">15</span><span style="font-family: Times New Roman, Times, Serif">% and 30% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer B represented </span><span style="font-size: 10pt">14</span><span style="font-family: Times New Roman, Times, Serif">% and 11% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">3)</span></td><td style="text-align: justify">Customer C represented 0% and 11% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">4)</span></td><td style="text-align: justify">Customer D represented 11% and 0% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 70.9pt"></td><td style="width: 18pt"><span style="font-size: 10pt">5)</span></td><td style="text-align: justify">Customer E represented 10% and 0% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company does not see any credit risk regarding the major trade receivable balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Use Of Estimates
UseOfEstimates
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>b.</b></td><td style="text-align: justify"><b>Use of estimates in preparation of financial statements</b></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, fair values of financial instruments, inventory write-offs, as well as in estimates used in applying the revenue recognition policy. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>d.</b></td><td style="text-align: justify"><b>Concentration of risk</b></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash and cash equivalents, trade receivables and other current assets. Cash and cash equivalents and restricted cash and cash equivalents are placed with banks and financial institutions in the United States and Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, present minimal credit risk with respect to those investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company’s trade receivables are derived primarily from telecommunication operators, the Company’s reseller customers and enterprises located mainly in the United States, Europe, and Asia.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Credit risk with respect to trade receivables exists to the full extent of the amounts presented in the consolidated financial statements. Management makes judgments as to its ability to collect outstanding accounts receivable and provides allowances for the applicable portion of accounts receivable when collection becomes doubtful.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Management provides allowances based upon a specific review of all significant outstanding invoices, analysis of its historical collection experience, and current economic trends. If the historical data used to calculate the allowance for credit losses does not reflect the Company’s future ability to collect outstanding accounts receivable, additional provisions for credit losses may be needed, and the future results of operations could be materially affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company has customers balances representing 10% or more of Trade receivables as follows:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer A represented </span><span style="font-size: 10pt">15</span><span style="font-family: Times New Roman, Times, Serif">% and 30% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer B represented </span><span style="font-size: 10pt">14</span><span style="font-family: Times New Roman, Times, Serif">% and 11% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">3)</span></td><td style="text-align: justify">Customer C represented 0% and 11% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">4)</span></td><td style="text-align: justify">Customer D represented 11% and 0% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 70.9pt"></td><td style="width: 18pt"><span style="font-size: 10pt">5)</span></td><td style="text-align: justify">Customer E represented 10% and 0% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company does not see any credit risk regarding the major trade receivable balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
1132000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
757000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1769000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
2158000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
2526000 usd
us-gaap Inventory Write Down
InventoryWriteDown
25000 usd
us-gaap Inventory Write Down
InventoryWriteDown
97000 usd
CY2024Q2 us-gaap Inventory Write Down
InventoryWriteDown
25 usd
CY2023Q2 us-gaap Inventory Write Down
InventoryWriteDown
90 usd
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
2000 usd
CY2020Q4 us-gaap Loans Payable
LoansPayable
20000000 ils
CY2020Q4 us-gaap Loans Payable
LoansPayable
6000000 usd
CY2020Q4 us-gaap Financing Receivable Loan In Process
FinancingReceivableLoanInProcess
3000000 usd
CY2021Q1 us-gaap Financing Receivable Loan In Process
FinancingReceivableLoanInProcess
2000000 usd
CY2024Q2 us-gaap Long Term Debt Percentage Bearing Variable Interest Rate
LongTermDebtPercentageBearingVariableInterestRate
0.096 pure
CY2021Q4 us-gaap Investment Company Increase From Payment By Affiliate And Gain Loss From Investment In Violation
InvestmentCompanyIncreaseFromPaymentByAffiliateAndGainLossFromInvestmentInViolation
1000000 usd
CY2021Q4 us-gaap Long Term Debt Percentage Bearing Variable Interest Rate
LongTermDebtPercentageBearingVariableInterestRate
0.096 pure
us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
1800000 usd
CY2022Q4 us-gaap Carrying Value Of Securities Sold Under Repurchase Agreements And Deposits Received For Securities Loaned
CarryingValueOfSecuritiesSoldUnderRepurchaseAgreementsAndDepositsReceivedForSecuritiesLoaned
2000000 usd
CY2023Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
2000000 usd
CY2024Q2 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
10900000 ils
CY2024Q2 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2933000 usd
CY2024Q1 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.096 pure
CY2024Q1 us-gaap Stock Issued1
StockIssued1
150000 usd
us-gaap Long Term Debt Average Amount Outstanding
LongTermDebtAverageAmountOutstanding
1160000 ils
us-gaap Long Term Debt Average Amount Outstanding
LongTermDebtAverageAmountOutstanding
308000 usd
CY2024Q1 us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.015 pure
CY2024Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1045000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
757000 usd
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1026000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1769000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
2158000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
2526000 usd
us-gaap Inventory Write Down
InventoryWriteDown
25000 usd
us-gaap Inventory Write Down
InventoryWriteDown
97000 usd
CY2024Q2 us-gaap Inventory Write Down
InventoryWriteDown
25 usd
CY2023Q2 us-gaap Inventory Write Down
InventoryWriteDown
90 usd
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
2000 usd
CY2020Q4 us-gaap Loans Payable
LoansPayable
20000000 ils
CY2020Q4 us-gaap Loans Payable
LoansPayable
6000000 usd
CY2020Q4 us-gaap Financing Receivable Loan In Process
FinancingReceivableLoanInProcess
3000000 usd
CY2021Q1 us-gaap Financing Receivable Loan In Process
FinancingReceivableLoanInProcess
2000000 usd
CY2024Q2 us-gaap Long Term Debt Percentage Bearing Variable Interest Rate
LongTermDebtPercentageBearingVariableInterestRate
0.096 pure
CY2021Q4 us-gaap Investment Company Increase From Payment By Affiliate And Gain Loss From Investment In Violation
InvestmentCompanyIncreaseFromPaymentByAffiliateAndGainLossFromInvestmentInViolation
1000000 usd
CY2021Q4 us-gaap Long Term Debt Percentage Bearing Variable Interest Rate
LongTermDebtPercentageBearingVariableInterestRate
0.096 pure
us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
1800000 usd
CY2022Q4 us-gaap Carrying Value Of Securities Sold Under Repurchase Agreements And Deposits Received For Securities Loaned
CarryingValueOfSecuritiesSoldUnderRepurchaseAgreementsAndDepositsReceivedForSecuritiesLoaned
2000000 usd
CY2023Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
2000000 usd
CY2024Q1 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2000000 ils
CY2024Q1 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
550000 usd
CY2024Q2 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
10900000 ils
CY2024Q2 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2933000 usd
CY2024Q1 us-gaap Stock Issued1
StockIssued1
150000 usd
us-gaap Long Term Debt Average Amount Outstanding
LongTermDebtAverageAmountOutstanding
308000 usd
CY2024Q1 us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.015 pure
us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.30 pure
CY2024Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1045000 usd
asns Royalties Paid Percentage
RoyaltiesPaidPercentage
1 pure
CY2024Q2 us-gaap Billed Contract Receivables
BilledContractReceivables
14300000 usd
CY2024Q2 us-gaap Interest Receivable
InterestReceivable
15825000 usd
asns Repaid Amount
RepaidAmount
10275000 usd
us-gaap Payments For Royalties
PaymentsForRoyalties
1119000 usd
CY2023 us-gaap Payments For Royalties
PaymentsForRoyalties
1062000 usd
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
190000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 asns Prefunded Warrants To Purchase Common Stock
PrefundedWarrantsToPurchaseCommonStock
754670 shares
CY2023Q2 asns Prefunded Warrants
PrefundedWarrants
754670 shares
CY2023Q2 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.0001
CY2023Q3 asns Exercise Of Prefunded Warrant
ExerciseOfPrefundedWarrant
754670 shares
CY2023Q3 asns Exercise Of Prefunded Warrant
ExerciseOfPrefundedWarrant
754670 shares
CY2023Q3 asns Exercise Price Of Prefunded Warrant
ExercisePriceOfPrefundedWarrant
0.0755
CY2023Q3 asns Exercise Price Of Prefunded Warrant
ExercisePriceOfPrefundedWarrant
0.0755
CY2023Q2 asns Payments To Underwriter
PaymentsToUnderwriter
291000 usd
CY2023Q2 asns Warrant Exercise Price Percentage
WarrantExercisePricePercentage
1.25 pure
CY2023Q4 us-gaap Proceeds From Payments For Long Term Loans For Related Parties
ProceedsFromPaymentsForLongTermLoansForRelatedParties
1500000 usd
CY2023Q4 asns Prefunded Warrants To Purchase Common Stock
PrefundedWarrantsToPurchaseCommonStock
970187 shares
CY2023Q4 asns Prefunded Warrants
PrefundedWarrants
970187 shares
CY2023Q4 asns Exercise Price Of Prefunded Warrant
ExercisePriceOfPrefundedWarrant
0.0001
asns Exercise Of Prefunded Warrant
ExerciseOfPrefundedWarrant
970187 shares
asns Exercise Price Of Prefunded Warrant
ExercisePriceOfPrefundedWarrant
0.097
CY2023Q4 asns Payments To Underwriter
PaymentsToUnderwriter
129000 usd
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
88983 shares
CY2023Q4 asns Offering Share Price
OfferingSharePrice
1.475
us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
a 1:1 exchange ratio. As further consideration, the Holder agrees to pay $0.125 cents per newly issued warrant outlined above for a total of $249.
asns Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisables
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisables
P5Y6M
asns Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable Remaining
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisableRemaining
P2Y
asns Existing Warrants Reduced Exercise Price
ExistingWarrantsReducedExercisePrice
-3437.5000 usd
CY2024Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1890 usd
asns Royalties Paid Percentage
RoyaltiesPaidPercentage
1 pure
CY2024Q2 us-gaap Billed Contract Receivables
BilledContractReceivables
14300000 usd
CY2024Q2 us-gaap Interest Receivable
InterestReceivable
15825000 usd
asns Repaid Amount
RepaidAmount
10275000 usd
us-gaap Payments For Royalties
PaymentsForRoyalties
1119000 usd
CY2023 us-gaap Payments For Royalties
PaymentsForRoyalties
1062000 usd
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
190000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 asns Prefunded Warrants To Purchase Common Stock
PrefundedWarrantsToPurchaseCommonStock
754670 shares
CY2023Q2 asns Prefunded Warrants
PrefundedWarrants
754670 shares
CY2023Q2 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.0001
CY2023Q3 asns Exercise Of Prefunded Warrant
ExerciseOfPrefundedWarrant
754670 shares
CY2023Q3 asns Exercise Of Prefunded Warrant
ExerciseOfPrefundedWarrant
754670 shares
CY2023Q3 asns Exercise Price Of Prefunded Warrant
ExercisePriceOfPrefundedWarrant
0.0755
CY2023Q3 asns Exercise Price Of Prefunded Warrant
ExercisePriceOfPrefundedWarrant
0.0755
CY2023Q2 asns Payments To Underwriter
PaymentsToUnderwriter
291000 usd
CY2023Q2 asns Warrant Exercise Price Percentage
WarrantExercisePricePercentage
1.25 pure
CY2023Q4 us-gaap Proceeds From Payments For Long Term Loans For Related Parties
ProceedsFromPaymentsForLongTermLoansForRelatedParties
1500000 usd
CY2023Q4 asns Prefunded Warrants To Purchase Common Stock
PrefundedWarrantsToPurchaseCommonStock
970187 shares
CY2023Q4 asns Prefunded Warrants
PrefundedWarrants
970187 shares
CY2023Q4 asns Exercise Price Of Prefunded Warrant
ExercisePriceOfPrefundedWarrant
0.0001
asns Exercise Of Prefunded Warrant
ExerciseOfPrefundedWarrant
970187 shares
asns Exercise Price Of Prefunded Warrant
ExercisePriceOfPrefundedWarrant
0.097
CY2023Q4 asns Payments To Underwriter
PaymentsToUnderwriter
129000 usd
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
88983 shares
CY2023Q4 asns Offering Share Price
OfferingSharePrice
1.475
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
230000 usd
us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
a 1:1 exchange ratio. As further consideration, the Holder agrees to pay $0.125 cents per newly issued warrant outlined above for a total of $249.
asns Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisables
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisables
P5Y6M
asns Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable Remaining
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisableRemaining
P2Y
asns Existing Warrants Reduced Exercise Price
ExistingWarrantsReducedExercisePrice
-3437.5000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
87764 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.63
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y1M9D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
21225 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1362 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.73
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
65102 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y7M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
58818 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.11
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y2M12D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
65102 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
93708 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
4.39
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
4.81
us-gaap Net Income Loss
NetIncomeLoss
-2064000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3159451000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1800665000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3998957000 usd
asns Pre Funded Warrants To Purchase Common Shares
PreFundedWarrantsToPurchaseCommonShares
841543 shares
asns Pre Funded Warrants To Purchase Common Shares
PreFundedWarrantsToPurchaseCommonShares
238979 shares
CY2024Q2 asns Pre Funded Warrants To Purchase Common Shares
PreFundedWarrantsToPurchaseCommonShares
258717 shares
asns Repurchase Of Common Stock
RepurchaseOfCommonStock
5896000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4000994 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2033747 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.63
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y1M9D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
21225 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.37
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.73
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y7M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
58818 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.11
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y2M12D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
65102 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
93708 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
4.39
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
4.81
us-gaap Net Income Loss
NetIncomeLoss
-2064000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3488000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-78000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1800665000 usd
asns Pre Funded Warrants To Purchase Common Shares
PreFundedWarrantsToPurchaseCommonShares
841543 shares
asns Pre Funded Warrants To Purchase Common Shares
PreFundedWarrantsToPurchaseCommonShares
238979 shares
asns Repurchase Of Common Stock
RepurchaseOfCommonStock
5896000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4000994 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2033747 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4257674 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
asns Revenue
Revenue
4158000 usd
asns Revenue
Revenue
3744000 usd
CY2024Q2 asns Revenue
Revenue
3431000 usd
CY2023Q2 asns Revenue
Revenue
1896000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
460000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
648000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
364000 usd
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
544000 usd
asns Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
155000 usd
CY2023 asns Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
356000 usd
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
251000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
460000 usd
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
251000 usd
CY2024Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
69977 shares
asns Existing Warrants Being Exercised
ExistingWarrantsBeingExercised
0.07 pure
us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
2.5
asns Exercise Price Percentage
ExercisePricePercentage
1.25 pure
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
asns Revenue
Revenue
4158000 usd
asns Revenue
Revenue
3744000 usd
CY2024Q2 asns Revenue
Revenue
3431000 usd
CY2023Q2 asns Revenue
Revenue
1896000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
460000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
648000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
364000 usd
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
544000 usd
asns Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
155000 usd
CY2023 asns Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
356000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
460000 usd
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
251000 usd
CY2024Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
69977 shares
asns Existing Warrants Being Exercised
ExistingWarrantsBeingExercised
0.07 pure
us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
2.5
asns Exercise Price Percentage
ExercisePricePercentage
1.25 pure
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
CY2023Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2024Q2 asns Exercise Of Pre Funded Warrants Into Common Stock.
ExerciseOfPreFundedWarrantsIntoCommonStock.
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
CY2023Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4257674 shares
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2024Q2 asns Exercise Of Pre Funded Warrants Into Common Stock.
ExerciseOfPreFundedWarrantsIntoCommonStock.
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
us-gaap Interest Expense
InterestExpense
usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
usd
asns Paymentto Short Term Restricted Bank Deposits
PaymenttoShortTermRestrictedBankDeposits
usd
asns Payments For Proceeds From Long Term Deposit
PaymentsForProceedsFromLongTermDeposit
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
asns Proceeds From Warrant Inducement Agreement
ProceedsFromWarrantInducementAgreement
usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
usd
us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
usd
CY2023Q2 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
usd
asns Issuance Costs Of The Warrant Inducement Agreement
IssuanceCostsOfTheWarrantInducementAgreement
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
asns Repurchase Of Common Stock
RepurchaseOfCommonStock
usd
CY2024Q2 asns Repurchase Of Common Stock
RepurchaseOfCommonStock
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2033747 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4000994 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4257674 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.72
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001141284
us-gaap Interest Expense
InterestExpense
usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
usd
asns Paymentto Short Term Restricted Bank Deposits
PaymenttoShortTermRestrictedBankDeposits
usd
asns Payments For Proceeds From Long Term Deposit
PaymentsForProceedsFromLongTermDeposit
usd
asns Proceeds From Warrant Inducement Agreement
ProceedsFromWarrantInducementAgreement
usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
usd
us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
usd
CY2023Q2 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
usd
asns Issuance Costs Of Common Stock Prefunded Warrants And Warrants
IssuanceCostsOfCommonStockPrefundedWarrantsAndWarrants
usd
asns Issuance Costs Of The Warrant Inducement Agreement
IssuanceCostsOfTheWarrantInducementAgreement
usd
us-gaap Net Income Loss
NetIncomeLoss
-3488000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q2 asns Repurchase Of Common Stock
RepurchaseOfCommonStock
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2033747 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4257674 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001141284

Files In Submission

Name View Source Status
asns-20240630_cal.xml Edgar Link unprocessable
0001213900-24-069173-index-headers.html Edgar Link pending
0001213900-24-069173-index.html Edgar Link pending
0001213900-24-069173.txt Edgar Link pending
0001213900-24-069173-xbrl.zip Edgar Link pending
asns-20240630.xsd Edgar Link pending
ea0211159-10q_actelisnet.htm Edgar Link pending
ea021115901ex31-1_actelisnet.htm Edgar Link pending
ea021115901ex31-2_actelisnet.htm Edgar Link pending
ea021115901ex32-1_actelisnet.htm Edgar Link pending
ea021115901ex32-2_actelisnet.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
asns-20240630_def.xml Edgar Link unprocessable
asns-20240630_lab.xml Edgar Link unprocessable
asns-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ea0211159-10q_actelisnet_htm.xml Edgar Link completed